CyLD deubiquitinase as a recurrent target in oncogenic processes;La déubiquitinase CyLD: Une cible récurrente dans les processus oncogéniques

Medecine/Sciences

Volumn 27, Issue 6-7, 2011, Pages 626-631

  Bonnet, Marion ^a   Courtois, Gilles ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYLD PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BIOLOGICAL MODEL; CELL TRANSFORMATION; DRUG ANTAGONISM; ENZYMOLOGY; FAMILIAL CANCER; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; SKIN TUMOR; TUMOR SUPPRESSOR GENE; UBIQUITINATION;

CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION; GENES, TUMOR SUPPRESSOR; HUMANS; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASTIC SYNDROMES, HEREDITARY; NF-KAPPA B; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEINS; UBIQUITINATION;

EID: 79960960785     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2011276015     Document Type: Article

References (32)

1. Takahashi M, Rapley E, Biggs PJ, et al. Linkage and LOH studies in 19 cylindromatosis families show no evidence of genetic heterogeneity and refine the CYLD locus on chromosome 16ql2-ql3. Hum Genet 2000;106:58-65. (Pubitemid 30156395)
2. Bignell GR, Warren W, Seal S, et al. Identification of the familial cylindromatosis tumoursuppressor gene. Nat Genet 2000;25:160-5. (Pubitemid 30394985)
3. Poblete Gutiérrez P, Eggermann T, Holler D, et al. Phenotype diversity in familial cylindromatosis: a frameshift mutation in the tumor suppressor gene CYLD underlies different tumors of shin appendages. J Invest Dermatol 2002;119:527-31. (Pubitemid 35001967)
4. Zheng G, Hu L, Huang W, et al. CYLD mutation causes multiple familial trichoepithelioma in three Chinese families. Hum Mutat 2004;23:400.
5. Pickart CM, Eddms MJ. Ubiquitin: structures, functions, mechanisms. Biochtm Biophys Acta 2004;1695:55-72. (Pubitemid 39585154)
6. Winget JM, Mayor T. The diversity of ubiquitin recognition: hot spots and varied specificity. Mol Cell 2010;38:627-35.
7. Steinmetz MO, Akhmanova A. Capturing protein tails by CAP-Gly domains. Trends Biochem Sci 2008;33:535-45.
8. Trompouki E, Hatzivassiliou E, Tsichntzis T, et al. CYLD is a deubiquitmating enzyme that negatively regulates NF-κB activation by TNFR family members. Mature 2003;424:793-6. (Pubitemid 37021710)
9. Kovalenko A, Chable-Bessia C, Cantarella G, et al. The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination. Mature 2003;424:801-5. (Pubitemid 37021712)
10. Brummelkomp TR, Nijman SM, Dirac AM, et al. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB. Nature 2003;424:797-801. (Pubitemid 37021711)
11. Reiley W, Zhang M, Sun SC. Negative regulation of JNK signaling by the tumor suppressor CYLD. J Biol Chem 2004;279:55161-7. (Pubitemid 40066510)
12. Stegmeier F, Sowa ME, Nalepa G, et al. The tumor suppressor CYLD regulates entry into mitosis. Proc Natl Acad Set USA 2007;104:8869-74. (Pubitemid 47175403)
13. Hitomi J, Christofferson DE, Ng A, et al. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 2008;135:1311-23.
14. Taunello DV, Haegebarth A, Kuper I, et al. Loss of the tumor suppressor CYLD enhances Wnt/β-catenin signaling through K63-linked ubiquitination of Dvl. Mol Cell 2010;37:607-19.
15. Sun SC. CYLD: a tumor suppressor deubiquitinase regulating NF-κB activation and diverse biological processes. Cell Death Differ 2010;17:25-34.
16. Poser I, Domínguez D, de Herreros AG, et al. Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor Snail. J Biol Chem 2001;276:24661-6.
17. Massoumi R, Kuphal S, Hellerbrand C, et al. Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med 2009;206:221-32.
18. Amiri KI, Richmond A. Role of NF-κB in melanoma. Cancer Metastasis Rev 2005;24:301-13.
19. Espmosa L, Cathelin S, D'Altri T, et al. The Notch/Hesl pathway sustains NF-κB activation through CYLD repression in T cell leukemia. Cancer Cell 2010;18:268-81.
20. Hirsch HA, lliopoulos D, Joshi A, et al. A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell 2010;17:348-61.
21. lliopoulos D, Jaeger SA, Hirsch HA, et al. STAT3 activation of miR-21 and miR-181b-l via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010;39:493-506.
22. An J, Mo D, Liu H, et al. Inactivation of the CYLD deubiquitinase by HPV E6 mediates hypoxia-induced NF-κB activation. Cancer Cell 2008;14:394-407.
23. Boehm JS, Zhao JJ, Yao J, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007;129:1065-79. (Pubitemid 46891036)
24. Hutti JE, Shen RR, Abbott DW, et al. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKε promotes cell transformation. Mol Cell 2009;34:461-72.
25. Reiley W, Zhang M, Wu X, et al. Regulation of the deubiquitmating enzyme CYLD by 1κB kinase γ-dependent phosphorylation. Mol Celt Biol 2005;25:3886-95. (Pubitemid 40617640)
26. Annunziata CM, Davis RE, Demchenko y, et al. Frequent engagement of the classical and alternative NF-κ pathways by diverse genetic abnormalities in multiple myeloma Cancer Cell 2007;12:115-30. (Pubitemid 47199123)
27. Schmidt A, Schmitz R, Giefing M, et al. Rare occurrence of biallelic CYLD gene mutations in classical Kodgkin lymphoma. Genes Chromosomes Cancer 2010;49:803-9.
28. Massoumi R. Ubiquitin chain cleavage: CYLD at work. Trends Biochem Sci 2010;35:392-9.
29. Hayden MS, Ghosh S. Shared principles in NF-κB signaling. Cell 2008;132:344-62.
30. Gautheron J, Courtois G. New functions of NEMO, the regulatory subunit of IKK. Med Sci (Paris) 2008, 24:954-9. (Pubitemid 352772926)
31. Kastner P, Chan S. Notch activation during T-cell leukemogenesis in Ikarosdeficient mice. Med Sci (Paris) 2006;22:708-10.
32. Grandvaux N. La kinase IKKε: de I'oncogenèse à la résistance au traitement du cancer du sein. Med Sci (Paris) 2011;27:619-25.